--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections--
--Clinical Trial Expected to Begin Enrollment in Q4 2022--
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections--
--Clinical Trial Expected to Begin Enrollment in Q4 2022--
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| ITRM | 0.4600 | +0.0070 | +1.55% |
| Iterum Therapeutics Plc | |||